This is not a new demonstration format. It is a replay of an existing public case validation process. Sourced from Charles River Associates' official public case, we first isolate the later-stage published answers, then reconstruct what was knowable at the time of the decision into an educational data package. Minerva Advisor completed one paid live run, and this video is a validation replay of an actual Decision Room session. It does not imply Charles River Associates endorsement, review, sponsorship, or certification, and it does not represent real customer results. This is an independent teaching simulation built on an official public source, not real correspondence.

The case opens with a second-generation diabetes asset carrying substantial commercial potential, facing direct competitive pressure and anticipated US market access challenges. Minerva holds a single decision object: whether to immediately commit full go-to-market resources, or first run a time-boxed, stoppable evidence gate on region, target population, and access pathway before deciding how to sequence investment.

This live run produced a five-item work receipt. It used one source document, identified four decision-relevant roles, separated confirmed facts from inferences and open questions, compared two concrete action paths, and retained three alternative explanations alongside one reversal condition. Executives see a launch sequencing judgment supported by this receipt, not a retrospective strategy summary written after the fact.

What is known: competitive pressure is real, US market access challenges are anticipated, and the team does not yet have jointly validated evidence across functions. What is unknown: the true cost of losing the competitive window, adoption probabilities across regions and segments, the actual severity of access barriers, and the minimum sequence and stop points for initial investment. Minerva does not treat commercial potential as equivalent to justification for full commitment.

The system retains its strongest counterargument against its own recommendation. If the competitive window is very short, running a regional and segment evidence gate first could impose a greater cost than it saves, and if that gate lacks clearly defined dependencies and stop conditions, it may not actually reduce risk. The stated reversal condition is precise: if competitor actions accelerate faster than the assumed pace allows, and sequencing dependencies turn out to be minimal, full commitment should proceed immediately rather than waiting on the gate.

CRA's later-published regional identification analysis, internal interviews, cross-functional workshops, function-level strategy development, and the resulting adjustments to resources, training, incentives, and market access investment were held out and excluded from the input package entirely. Minerva had no advance knowledge of the official launch approach when it produced this recommendation.

Three advisors cross-check the same judgment. Marcus distills the decision down to what launch evidence is actually required before full commitment. Sofia simulates second-order consequences across strategy, access, commercial and medical functions, and decision-makers. Evelyn directly challenges whether pursuing validation sacrifices the competitive window. All three independently converge on the same conclusion: a time-boxed, stoppable regional and access evidence gate.

Evelyn adds a caveat: a phased path is only safer when the competitive window is long enough to absorb it. If competitors are approaching a critical threshold, waiting could prove more irreversible than a misplaced investment. This is the test of whether executive input can actually move the system's judgment. The executive adds a direction: quantify the competitive window and the cost of market access delay first; if that delay loss exceeds the risk of phased validation, accelerate a scope-limited investment. Minerva records this as a response receipt. The original judgment stands, but the reversal signal is now sharper and more specific.

Immediate full launch maximizes speed against the competitive window, but if adoption and access assumptions prove wrong, it amplifies an investment that cannot be undone. A time-boxed regional, population, and access gate preserves room to adjust, at the cost of potentially delaying full commitment. The executive selects the second path, the evidence gate, while explicitly retaining the window-based reversal option as an active trigger.

The committed action is specific and time-bound. The Chair directs the Market Access and Commercial and Medical teams to define the minimum evidence set and stop conditions for the first regional, population, and access gate before any resource allocation proceeds. Within three weeks, that team is to report findings on the competitive window, regional and segment adoption, access barriers, resource dependencies, and stop conditions.

This Charles River Associates case passed ten out of ten decision-quality checks. The Decision Room's actual English-language run used four model calls, delivering the first decision in fifteen point five five four seconds and completing the full result in twenty-two point eight seven one seconds, passing both the thirty-second first-decision threshold and the forty-five-second complete-result threshold. Decision quality and performance status both passed. This remains a single case test, not a guarantee of production-level service, and it does not constitute medical, pharmaceutical launch, or investment advice, nor a claim that any launch outcome has occurred.